A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTabs™ in Patients Undergoing an Elective Abdominal Liposuction Procedure

Talphera, Inc1 site in 1 country40 target enrollmentJune 2009

ConditionsSedation Anxiety Pain

InterventionsSublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)Placebo NanoTab™

DrugsSublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)Placebo NanoTab™

Overview

Phase: Phase 2
Intervention: Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)
Conditions: Sedation
Sponsor: Talphera, Inc
Enrollment: 40
Locations: 1
Primary Endpoint: Summed Richmond Agitation Sedation Score (RASS) Over the 4-hour Study Period (SRS-4)
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the safety and effectiveness of a study medication that contains a combination of a pain medication, sufentanil, and a sedative, triazolam. This drug is being designed to provide mild sedation as well as reduce anxiety and pain before and during a procedure (in this case elective abdominal liposuction).

Registry

clinicaltrials.gov

Start Date

June 2009

End Date

September 2009

Last Updated

11 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Talphera, Inc

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patient must have provided written informed consent to participate in the study.
•Male or female patient between 18 to 60 (inclusive) years of age.
•Patient is planning to undergo an elective outpatient abdominal liposuction procedure.
•Patient must be classified as American Society of Anesthesiologists (ASA) class I - III.
•Patient must have Body Mass Index \[BMI = weight (kg)/height (m2)\] between 20 and 35, inclusively.
•Female patients of childbearing potential must be using an effective method of birth control at the time of the screening visit and for 30 days following the dosing of study medication. Acceptable methods of birth control include oral or transdermal contraceptives, condom, spermicidal foam, intrauterine device (IUD), progestin implant or injection, abstinence, vaginal ring, or sterilization of partner. The reason for non-childbearing potential, such as bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or postmenopausal for ≥1 year, must be specified. Patients using hormonal forms of contraception must also be willing to use a barrier method of contraception from screening through 30 days following the dose of study medication.
•Patient is willing to receive antibiotics as per the normal practice of the surgeon.
•Patient understands that preoperative analgesics or anxiolytics are not permitted.
•Patient is willing to avoid caffeine and alcohol use within 24 hours before the procedure.
•The patient must be willing and able to understand the study procedures and the use of pain and anxiety scales, and to communicate meaningfully with the study personnel.

Exclusion Criteria

•Patient who is expected to require less than 400 cc or more than 700 cc of abdominal fat removal during the procedure.
•Patient has previously not responded to opioid analgesics for treatment of pain.
•Patient has previously not responded to benzodiazepines for treatment of anxiety.
•Patient is currently taking any opioid or has taken any opioid for more than 7 consecutive days of daily use within the past 3 months prior to the procedure.
•Patient is currently taking any benzodiazepine or has taken any benzodiazepine for more than 7 consecutive days within the past 3 months prior to the procedure.
•Patient is taking monoamine oxidase inhibitors (MAOIs), or have taken MAOIs within 14 days prior to enrolling in the study.
•Patient has an allergy or hypersensitivity to opioids.
•Patient who is currently taking anti-inflammatory drugs, including steroids.
•Use of drugs which are P450 3A4 inducers or inhibitors within 30 days of dosing including alprazolam, chlorpheniramine, cimetidine, fluoxetine, haloperidol, ketoconazole, itraconazole, erythromycin, clarithromycin, sildenafil, simvastatin, St. John's Wort.
•Patient who is taking calcium channel blockers or beta blockers.

Arms & Interventions

1

single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™

Intervention: Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)

2

single dose of sublingual Placebo NanoTab™

Intervention: Placebo NanoTab™

Outcomes

Primary Outcomes

Summed Richmond Agitation Sedation Score (RASS) Over the 4-hour Study Period (SRS-4)

Time Frame: 4 hour study period

The primary efficacy endpoint of the study is the sedation level as assessed by the 10-point RASS, where unarousable is graded as minus 5 (- 5) and combative is graded as plus 4 (+ 4). The RASS was assessed at 15 time points throughout the four hour study period.